Medical Cannabis Studies

• View All (505)

Drug-drug interaction between clobazam and cannabidiol in children with refractory epilepsy. (2015)

Refractory epilepsy is when epileptic seizures are so frequent that they limit the patient’s ability to live fully according to their desires and their mental and physical capacity. The objective of this study was under an expanded access investigational new drug (IND) trial, cannabidiol (CBD) is being studied as a possible adjuvant treatment of refractory epilepsy in children. It was concluded that (CBD) is a safe and effective treatment of refractory epilepsy in patients receiving treatment with clobazam (CLB). View study
Duration of use of oral cannabis extract in a cohort of pediatric epilepsy patients (2017)

The results of this study highlight the need for rigorous clinical studies to characterize the efficacy and safety of oral cannabis extracts and their use in the treatment of epilepsy, since despite the legalization of the product in the United States, its effectiveness it is not yet clear. View study
Early increase of cannabinoid receptor density after experimental traumatic brain injury in the newborn piglet (2014)

View study
Effect of marijuana smoking on pulmonary disease in HIV-infected and uninfected men: a longitudinal cohort study. (2019)

Lung disease is a common comorbidity in people with HIV / AIDS, independent of smoking status. The results found in this longitudinal study indicate marijuana smoking was associated with lung disease independent of tobacco smoking and other risk factors in HIV-infected individuals. These findings could reduce the risk of lung disease in high-risk populations. View study
Effect of sublingual application of cannabinoids on intraocular pressure (2006)

These investigations demonstrated that by applying a low dose of delta-9-tetrahydrocannabinol (D-9-THC) and cannabidiol (CBD) to patients with ocular hypertension or early primary open-angle glaucoma, to evaluate the effect on intraocular pressure (IOP), and the safety and tolerability of the oromucosal administration. It was concluded that a single sublingual dose of 5 mg of D-9-THC temporarily reduced IOP and was well tolerated by most patients. View study
Effects of anandamide in migraine: data from an animal model (2010)

Rats were used in this study to evaluate the effects of anandamide on migraine. With the results of this study it was possible to verify that a dysfunction of the endocannabinoid system can contribute to the development of migraine attacks and that a pharmacological modulation of CB receptors can be useful for the treatment of migraine pain. View study
Effects of Cannabidiol (CBD) on Regional Cerebral Blood (2003)

The evaluation of brain regions in which the anxiolytic effects of CBD were predicted early revealed two groups of voxel of uptake of ECD significantly decreased in the CBD in correspondence with the placebo condition (po0.001, uncorrected for multiple comparisons). In addition there was a set of higher activity with CBD than placebo in the left parahipocampic gyrus (po0.001). These results suggest that CBD has anxiolytic properties and that these effects are mediated by an action in areas of the limbic and paralimbic brain. View study
Effects of cannabinoid drugs on the deficit of prepulse inhibition of startle in an animal model of schizophrenia: the SHR strain (2014)

View study
Effects of cannabis on cognitive function in patients with multiple sclerosis (2011)

The objective of the study was to determine the neuropsychological effects of cannabis use in patients with multiple sclerosis (MS). The results showed that the prolonged consumption of inhaled or ingested street cannabis in patients with MS is associated with worse performance in the cognitive domains usually affected in this population. View study
Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study (2005)

According to these experiments of animal models, there is an important relationship between obesity, cardiovascular risks and the CB1 cannabinoid receptor, which when blocked by the inverse agonist Rimonabant promotes the decrease in body weight and waist circumference, also decreasing the cardiovascular risk. View study
Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study (2004)

Painful muscle spasms are among the most common and distressing symptoms of multiple sclerosis (MS) and have a great influence on the quality of life. In this study the effect of a standardized Cannabis sativa plant extract administered orally is investigated. in patients with (MS) with poorly controlled spasticity. View study
End of Life Care for Infants, Children and Young People with Life-Limiting Conditions: Planning and Management (2016)

In modern Western society, the family or caregivers do not expect the death of a child, and therefore it has broad and devastating consequences. This guide is directed to all pediatric care providers at the end of life, whatever their level of practice, and also to children and young people with conditions that limit their lives and to their parents or caregivers. View study